|
1
|
von Gruenigen VE, Frasure HE, Kavanagh MB,
Lerner E, Waggoner SE and Courneya KS: Feasibility of a lifestyle
intervention for ovarian cancer patients receiving adjuvant
chemotherapy. Gynecol Oncol. 122:328–333. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shikany JM, Flood AP, Kitahara CM, Hsing
AW, Meyer TE, Willcox BJ, Redden DT and Ziegler RG: Dietary
carbohydrate, glycemic index, glycemic load, and risk of prostate
cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial (PLCO) cohort. Cancer Causes Control. 22:995–1002.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Markman M, Moon J, Wilczynski S, Lopez AM,
Rowland KM Jr, Michelin DP, Lanzotti VJ, Anderson GL and Alberts
DS: Single agent carboplatin versus carboplatin plus pegylated
liposomal doxorubicin in recurrent ovarian cancer: Final survival
results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol.
116:323–325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang J, Sharma A, Ghamande SA, Bush S,
Ferris D, Zhi W, He M, Wang M, Wang X, Miller E, et al: Serum
protein profile at remission can accurately assess therapeutic
outcomes and survival for serous ovarian cancer. PLoS One.
8:e783932013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Havrilesky LJ, Pokrzywinski R, Revicki D,
Higgins RV, Nycum LR, Kohler MF, Berchuck A, Myers ER and Secord
AA: Cost-effectiveness of combination versus sequential docetaxel
and carboplatin for the treatment of platinum-sensitive, recurrent
ovarian cancer. Cancer. 118:386–391. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Darcy KM, Tian C and Reed E: A Gynecologic
Oncology Group study of platinum-DNA adducts and excision repair
cross-complementation group 1 expression in optimal, stage III
epithelial ovarian cancer treated with platinum-taxane
chemotherapy. Cancer Res. 67:4474–4481. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van de Vaart PJ, van der Vange N,
Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink
WW, Beijnen JH, Bartelink H and Begg AC: Intraperitoneal cisplatin
with regional hyperthermia in advanced ovarian cancer:
Pharmacokinetics and cisplatin-DNA adduct formation in patients and
ovarian cancer cell lines. Eur J Cancer. 34:148–154. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stefanou DT, Bamias A, Episkopou H,
Kyrtopoulos SA, Likka M, Kalampokas T, Photiou S, Gavalas N,
Sfikakis PP, Dimopoulos MA, et al: Aberrant DNA damage response
pathways may predict the outcome of platinum chemotherapy in
ovarian cancer. PLoS One. 10:e01176542015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ahluwalia A, Hurteau JA, Bigsby RM and
Nephew KP: DNA methylation in ovarian cancer. II. Expression of DNA
methyltransferases in ovarian cancer cell lines and normal ovarian
epithelial cells. Gynecol Oncol. 82:299–304. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu H, Fang J, Zhang J, Zhao Z, Liu L,
Wang J, Xi Q and Gu M: miR-182 targets CHL1 and controls tumor
growth and invasion in papillary thyroid carcinoma. Biochem Biophys
Res Commun. 450:857–862. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu H, Liu Y, Bai L, Kijlstra A and Yang P:
Predisposition to Behçet's disease and VKH syndrome by genetic
variants of miR-182. J Mol Med Berl. 92:961–967. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tang H, Wang Z, Liu Q, Liu X, Wu M and Li
G: Disturbing miR-182 and −381 inhibits BRD7 transcription and
glioma growth by directly targeting LRRC4. PLoS One. 9:e841462014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen T, Ueda Y, Xie S and Li E: A novel
DNMT3a isoform produced from an alternative promoter localizes to
euchromatin and its expression correlates with active de novo
methylation. J Biol Chem. 277:38746–38754. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bai X, Song Z, Fu Y, Yu Z, Zhao L, Zhao H,
Yao W, Huang D, Mi X, Wang E, et al: Clinicopathological
significance and prognostic value of DNA methyltransferase 1, 3a,
and 3b expressions in sporadic epithelial ovarian cancer. PLoS One.
7:e400242012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mostowska A, Sajdak S, Pawlik P, Lianeri M
and Jagodzinski PP: DNMT1, DNMT3a and DNMT3B gene variants in
relation to ovarian cancer risk in the Polish population. Mol Biol
Rep. 40:4893–4899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zou Y, Huang MZ, Liu FY, Yang BC, Wang LQ,
Wang F, Yu XH, Wan L, Wan XD, Xu XY, et al: Absence of DICER1,
CTCF, RPL22, DNMT3a, TRRAP, IDH1 and IDH2 hotspot mutations in
patients with various subtypes of ovarian carcinomas. Biomed Rep.
3:33–37. 2015.PubMed/NCBI
|
|
17
|
Olivieri F, Ahtiainen M, Lazzarini R,
Pöllänen E, Capri M, Lorenzi M, Fulgenzi G, Albertini MC, Salvioli
S, Alen MJ, et al: Hormone replacement therapy enhances IGF-1
signaling in skeletal muscle by diminishing miR-182 and miR-223
expressions: A study on postmenopausal monozygotic twin pairs.
Aging Cell. 13:850–861. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wallis CJ, Gordanpour A, Bendavid JS,
Sugar L, Nam RK and Seth A: MiR-182 is associated with growth,
migration and invasion in prostate cancer via suppression of FOXO1.
J Cancer. 6:1295–1305. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun J, Ji J, Huo G, Song Q and Zhang X:
miR-182 induces cervical cancer cell apoptosis through inhibiting
the expression of DNMT3a. Int J Clin Exp Pathol. 8:4755–4763.
2015.PubMed/NCBI
|
|
20
|
Mirza S, Sharma G, Parshad R, Gupta SD,
Pandya P and Ralhan R: Expression of DNA methyltransferases in
breast cancer patients and to analyze the effect of natural
compounds on DNA methyltransferases and associated proteins. J
Breast Cancer. 16:23–31. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Endo S, Amano M, Nishimura N, Ueno N, Ueno
S, Yuki H, Fujiwara S, Wada N, Hirata S, Hata H, et al:
Immunomodulatory drugs act as inhibitors of DNA methyltransferases
and induce PU.1 up-regulation in myeloma cells. Biochem Biophys Res
Commun. 469:236–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu C, Xu P, Chen D, Fan X, Xu Y, Li M,
Yang X and Wang C: Roles of autophagy-related genes Beclin-1 and
LC3 in the development and progression of prostate cancer and
benign prostatic hyperplasia. Biomed Rep. 1:855–860.
2013.PubMed/NCBI
|
|
23
|
Pappano WN, Zhang Q, Tucker LA, Tse C and
Wang J: Genetic inhibition of the atypical kinase Wee1 selectively
drives apoptosis of p53 inactive tumor cells. BMC Cancer.
14:4302014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Marjanović M, Sánchez-Huertas C, Terré B,
Gómez R, Scheel JF, Pacheco S, Knobel PA, Martínez-Marchal A, Aivio
S, Palenzuela L, et al: CEP63 deficiency promotes p53-dependent
microcephaly and reveals a role for the centrosome in meiotic
recombination. Nat Commun. 6:76762015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Korch C, Spillman MA, Jackson TA, Jacobsen
BM, Murphy SK, Lessey BA, Jordan VC and Bradford AP: DNA profiling
analysis of endometrial and ovarian cell lines reveals
misidentification, redundancy and contamination. Gynecol Oncol.
127:241–248. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma PJ, Zhang H, Li R, Wang YS, Zhang Y and
Hua S: P53-mediated repression of the reprogramming in cloned
bovine embryos through direct interaction with HDAC1 and indirect
interaction with DNMT3a. Reprod Domest Anim. 50:400–409. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tang LJ, Li Y, Liu YL, Wang JM, Liu DW and
Tian QB: USP12 regulates cell cycle progression by involving c-Myc,
cyclin D2 and BMI-1. Gene. 578:92–99. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Perez EA, Jenkins RB, Dueck AC, Wiktor AE,
Bedroske PP, Anderson SK, Ketterling RP, Sukov WR, Kanehira K, Chen
B, et al: C-MYC alterations and association with patient outcome in
early-stage HER2-positive breast cancer from the north central
cancer treatment group N9831 adjuvant trastuzumab trial. J Clin
Oncol. 29:651–659. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nguyen JC, Kubik MJ, Broome HE, Curtin PT,
Dell'Aquila ML and Wang HY: Successful treatment of both double
minute of C-MYC and BCL-2 rearrangement containing large B-cell
lymphoma with subsequent unfortunate development of therapy-related
acute myeloid leukemia with t(3;3)(q26.2;q21). Pathol Res Pract.
211:883–891. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stewart HJ, Horne GA, Bastow S and
Chevassut TJ: BRD4 associates with p53 in DNMT3a-mutated leukemia
cells and is implicated in apoptosis by the bromodomain inhibitor
JQ1. Cancer Med. 2:826–835. 2013. View
Article : Google Scholar : PubMed/NCBI
|
